DID YOU KNOW? DTIC has over 3.5 million final reports on DoD funded research, development, test, and evaluation activities available to our registered users. Click
HERE to register or log in.
Accession Number:
AD1093771
Title:
Iron Chelation Enhances TAM and Triple-Negative Breast Cancer Cell Death
Report Date:
2018-10-01
Abstract:
The goal of this study is to complete preclinical testing of Deferiprone (DFP), an iron chelator in clinical use for nononcologic diseases. We propose to demonstrate the sensitivity of TNBC to DFP as a single agent, and in combination with immune modulation therapy (checkpoint inhibitors) and chemotherapy (paclitaxel). We will determine if imaging of changes in iron content using magnetic resonance imaging can serve as a biomarker of DFP efficacy. Studies were planned to be performed sequentially by first studying in vitro effects of DFP, followed by in vivo effects, followed by the effects of adding other drugs (checkpoint inhibitors and paclitaxel). Effects of these drugs on cell cycle and immune effects were also proposed.
Document Type:
Conference:
Journal:
Pages:
60
File Size:
5.37MB
W81XWH-17-1-0525
(W81XWH1710525);
Contracts:
Grants:
Distribution Statement:
Approved For Public Release
